Home › Funds › LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA › REGN
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA position in REGN
REGENERON PHARMACEUTICALS · Health Care
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA reported holding 65,875 shares of REGN (REGENERON PHARMACEUTICALS) in its Q2 2026 13F filing — a position valued at US$41.1M, representing 0.40% of its reported portfolio and ranking #49 among its reported holdings. LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's REGN position evolved
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA first disclosed a stake in REGN in Q3 2023 at 43,917 shares (US$36.0M). The position peaked in Q2 2024 at 103,680 shares, worth US$113.5M. Across 12 filings, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 65,875 shares valued at US$41.1M — a reduction of -6,555 shares quarter over quarter.. Notable position changes include a 40% increase in Q4 2023 (shares rose 10% over the following quarter), a 42% increase in Q1 2024 (shares rose 9% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 43.92K | $35.96M | New |
| Q4 2023 | 61.45K | $57.93M | Add |
| Q1 2024 | 87.27K | $78.56M | Add |
| Q2 2024 | 103.68K | $113.53M | Add |
| Q3 2024 | 109.48K | $101.70M | Add |
| Q4 2024 | 106.09K | $72.64M | Reduce |
| Q1 2025 | 96.47K | $56.71M | Reduce |
| Q2 2025 | 99.91K | $52.45M | Add |
| Q3 2025 | 91.73K | $52.81M | Reduce |
| Q4 2025 | 86.97K | $67.08M | Reduce |
| Q1 2026 | 72.43K | $54.24M | Reduce |
| Q2 2026 | 65.88K | $41.08M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About REGN and 13F data
REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 31 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), LOOMIS SAYLES & CO L P (US$1.16B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding REGN
- Dodge & Cox 4.87M sh · $3.04B · Q2 2026
- DODGE & COX 4.87M sh · $3.04B · Q2 2026
- LOOMIS SAYLES & CO L P 1.86M sh · $1.16B · Q2 2026
More on LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA
FAQ
How long has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA held REGN?
LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA has disclosed REGN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA's current position in REGN?
As of Q2 2026, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA holds 65.88K shares of REGN (REGENERON PHARMACEUTICALS), valued at $41.08M, representing 0.40% of its reported portfolio and ranking #49.
Has LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA been buying or selling REGN?
In the latest 13F filing (Q2 2026), LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS LLP/MA reduced its position in REGN. The position peaked in Q2 2024 at 103.68K shares.
Which other funds hold REGN?
Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, LOOMIS SAYLES & CO L P, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.